Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's strong cash position of approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables at the end of Q3 2025 highlights its financial stability and potential for continued investment in research and development. Additionally, positive developments in the ongoing Phase 3 DYNASTY-Breast02 trial for BNT323 and the promising immune responses generated by their LP.8.1-adapted monovalent COVID-19 vaccine underscore BioNTech's innovative capabilities in both oncology and infectious disease markets. These factors contribute to a favorable outlook for the company's growth prospects and long-term success in the biotechnology sector.

Bears say

The negative outlook on BioNTech's stock is driven by multiple risks, including the potential for negative clinical data from several pipeline programs, slower-than-expected market uptake of its therapies, and regulatory uncertainties which could hinder commercial success. Additionally, the company reported a net loss per diluted share of €0.12 for the third quarter of 2025 and is projected to have a full-year net loss per diluted share of €3.99, indicating ongoing financial challenges. Moreover, the heightened volatility in the COVID-19 vaccine market and a more restrictive regulatory environment in the U.S. may distract investors from BioNTech’s long-term oncology initiatives.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.